Association of Interleukin-10 (IL10) promoter genotypes with nasopharyngeal carcinoma risk in Taiwan

Anticancer Research

Volumn 33, Issue 8, 2013, Pages 3391-3396

  Tsai, Chia Wen ^a,b   Tsai, Ming Hsui ^b   Shih, Liang Chun ^b   Chang, Wen Shin ^a,b   Lin, Cheng Chieh ^b   Bau, Da Tian ^a,b  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

IL10; Nasopharyngeal carcinoma; Polymorphism

Indexed keywords

INTERLEUKIN 10;

ADULT; ALLELE; ARTICLE; BETEL NUT; CANCER RISK; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRINKING BEHAVIOR; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SMOKING HABIT; TAIWAN;

IL10; NASOPHARYNGEAL CARCINOMA; POLYMORPHISM;

CASE-CONTROL STUDIES; DEMOGRAPHY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-10; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RISK FACTORS; SMOKING; TAIWAN;

EID: 84883296094     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Cao SM, Simons MJ and Qian CN: The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer 30: 114-119, 2011.
2. Chan AT, Teo PM and Johnson PJ: Nasopharyngeal carcinoma. Ann Oncol 13: 1007-1015, 2002.
3. Yu MC and Yuan JM: Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 12: 421-429, 2002.
4. Cancer Registration System Annual Report in Taiwan, ROC. Department of Health Executive Yuan, Annual Report of Department of Health Executive Yuan, 2010.
5. Niedobitek G, Hansmann ML, Herbst H, Young LS, Dienemann D, Hartmann CA, Finn T, Pitteroff S, Welt A and Anagnostopoulos I: Epstein-Barr virus and carcinomas: Undifferentiated carcinomas but not squamous cell carcinomas of the nasopharynx are regularly associated with the virus. J Pathol 165: 17-24, 1991.
6. Zong YS, Sham JS, Ng MH, Ou XT, Guo YQ, Zheng SA, Liang JS and Qiu H: Immunoglobulin A against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma. Cancer 69: 3-7, 1992.
7. Armstrong RW, Imrey PB, Lye MS, Armstrong MJ, Yu MC and Sani S: Nasopharyngeal carcinoma in Malaysian Chinese: Salted fish and other dietary exposures. Int J Cancer 77: 228-235, 1998.
8. Feng XL, Zhou W, Li H, Fang WY, Zhou YB, Yao KT and Ren CP: The DLC-1 -29A/T polymorphism is not associated with nasopharyngeal carcinoma risk in Chinese population. Genet Test 12: 345-349, 2008.
9. Shih LC, Tsai CW, Tsai MH, Tsou YA, Chang WS, Li FJ, Lee MH and Bau DT: Association of cyclin D1 genotypes with nasopharyngeal carcinoma risk. Anticancer Res 32: 1093-1098, 2012.
10. Tsou YA, Tsai CW, Tsai MH, Chang WS, Li FJ, Liu YF, Chiu CF, Lin CC and Bau DT: Association of caveolin-1 genotypes with nasopharyngeal carcinoma susceptibility in Taiwan. Anticancer Res 31: 3629-3632, 2011.
11. Xu FH, Xiong D, Xu YF, Cao SM, Xue WQ, Qin HD, Liu WS, Cao JY, Zhang Y, Feng QS, Chen LZ, Li MZ, Liu ZW, Liu Q, Hong MH, Shugart YY, Zeng YX, Zeng MS and Jia WH: An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein-Barr virus activation. J Natl Cancer Inst 104: 1396-1410, 2012.
12. Ji X, Zhang W, Xie C, Wang B, Zhang G and Zhou F: Nasopharyngeal carcinoma risk by histologic type in central China: Impact of smoking, alcohol and family history. Int J Cancer 129: 724-732, 2011.
13. Cao Y, Miao XP, Huang MY, Deng L, Liang XM, Lin DX, Zeng YX and Shao JY: Polymorphisms of methylenetetrahydrofolate reductase are associated with a high risk of nasopharyngeal carcinoma in a smoking population from Southern China. Mol Carcinog 49: 928-934, 2010.
14. Mocellin S, Marincola FM and Young HA: Interleukin-10 and the immune response against cancer: A counterpoint. J Leukoc Biol 78: 1043-1051, 2005.
15. Uwatoko N, Tokunaga T, Hatanaka H, Osada H, Kawakami T, Yamazaki H, Abe Y, Kijima H, Ueyama Y and Nakamura M: Expression of interleukin-10 is inversely correlated with distant metastasis of renal cell carcinoma. Int J Oncol 20: 729-733, 2002.
16. Neuner A, Schindel M, Wildenberg U, Muley T, Lahm H and Fischer JR: Prognostic significance of cytokine modulation in non-small cell lung cancer. Int J Cancer 101: 287-292, 2002.
17. Kozlowski L, Zakrzewska I, Tokajuk P and Wojtukiewicz MZ: Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst 48: 82-84, 2003. [in Poland]
18. De Vita F, Orditura M, Galizia G, Romano C, Roscigno A, Lieto E and Catalano G: Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest 117: 365-373, 2000.
19. Budiani DR, Hutahaean S, Haryana SM, Soesatyo MH and Sosroseno W: Interleukin-10 levels in Epstein-Barr virusassociated nasopharyngeal carcinoma. J Microbiol Immunol Infect 35: 265-268, 2002.
20. Fujieda S, Lee K, Sunaga H, Tsuzuki H, Ikawa H, Fan GK, Imanaka M, Takenaka H and Saito H: Staining of interleukin-10 predicts clinical outcome in patients with nasopharyngeal carcinoma. Cancer 85: 1439-1445, 1999.
21. Kingo K, Ratsep R, Koks S, Karelson M, Silm H and Vasar E: Influence of genetic polymorphisms on interleukin-10 mRNA expression and psoriasis susceptibility. J Dermatol Sci 37: 111-113, 2005.
22. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ and Hutchinson IV: An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24: 1-8, 1997.
23. Tseng LH, Lin MT, Shau WY, Lin WC, Chang FY, Chien KL, Hansen JA, Chen DS and Chen PJ: Correlation of interleukin-10 gene haplotype with hepatocellular carcinoma in Taiwan. Tissue Antigens 67: 127-133, 2006.
24. Langsenlehner U, Krippl P, Renner W, Yazdani-Biuki B, Eder T, Koppel H, Wascher TC, Paulweber B and Samonigg H: Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk. Breast Cancer Res Treat 90: 113-115, 2005.
25. Havranek E, Howell WM, Fussell HM, Whelan JA, Whelan MA and Pandha HS: An interleukin-10 promoter polymorphism may influence tumor development in renal cell carcinoma. J Urol 173: 709-712, 2005.
26. Wei YS, Kuang XH, Zhu YH, Liang WB, Yang ZH, Tai SH, Zhao Y and Zhang L: Interleukin-10 gene promoter polymorphisms and the risk of nasopharyngeal carcinoma. Tissue Antigens 70: 12-17, 2007.
27. Wu HC, Chang CH, Tsou YA, Tsai CW, Lin CC and Bau DT: Significant association of caveolin-1 (CAV1) genotypes with prostate cancer susceptibility in Taiwan. Anticancer Res 31: 745-749, 2011.
28. Tsai CW, Tsai MH, Tsou YA, Shih LC, Tseng HC, Chang WS, Ho CY, Lee HZ and Bau DT: The joint effect of smoking and hOGG1 genotype on oral cancer in Taiwan. Anticancer Res 32: 3799-3803, 2012.
29. Pratesi C, Bortolin MT, Bidoli E, Tedeschi R, Vaccher E, Dolcetti R, Guidoboni M, Franchin G, Barzan L, Zanussi S, Caruso C and De Paoli P: Interleukin-10 and interleukin-18 promoter polymorphisms in an Italian cohort of patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Immunol Immunother 55: 23-30, 2006.
30. Farhat K, Hassen E, Gabbouj S, Bouaouina N and Chouchane L: Interleukin-10 and interferon-gamma gene polymorphisms in patients with nasopharyngeal carcinoma. Int J Immunogenet 35: 197-205, 2008.
31. Seifart C, Plagens A, Dempfle A, Clostermann U, Vogelmeier C, von Wichert P and Seifart U: TNF-α, TNF-β, IL-6, and IL-10 polymorphisms in patients with lung cancer. Dis Markers 21: 157-165, 2005.
32. Shih CM, Lee YL, Chiou HL, Hsu WF, Chen WE, Chou MC and Lin LY: The involvement of genetic polymorphism of IL-10 promoter in non-small cell lung cancer. Lung Cancer 50: 291-297, 2005.
33. Stanczuk GA, Sibanda EN, Perrey C, Chirara M, Pravica V, Hutchinson IV and Tswana SA: Cancer of the uterine cervix may be significantly associated with a gene polymorphism coding for increased IL-10 production. Int J Cancer 94: 792-794, 2001.
34. Pooja S, Chaudhary P, Nayak LV, Rajender S, Saini KS, Deol D, Kumar S, Bid HK and Konwar R: Polymorphic variations in IL- 1β, IL-6 and IL-10 genes, their circulating serum levels and breast cancer risk in Indian women. Cytokine 60: 122-128, 2012.
35. Kesarwani P, Ahirwar DK, Mandhani A, Singh AN, Dalela D, Srivastava AN and Mittal RD: IL-10 -1082 G>A: A risk for prostate cancer but may be protective against progression of prostate cancer in North Indian cohort. World J Urol 27: 389-396, 2009.
36. Zeng X, Li Y, Liu T and Zhang J: Diverse H. pylori strains, IL-10 promoter polymorphisms with high morbidity of gastric cancer in Hexi area of Gansu Province, China. Mol Cell Biochem 362: 241-248, 2012.
37. Lu W, Pan K, Zhang L, Lin D, Miao X and You W: Genetic polymorphisms of interleukin (IL)-1B, IL-1RN, IL-8, IL-10 and tumor necrosis factor α and risk of gastric cancer in a Chinese population. Carcinogenesis 26: 631-636, 2005.
38. Pan F, Tian J, Pan YY and Zhang Y: Association of IL-10 -1082 promoter polymorphism with susceptibility to gastric cancer: Evidence from 22 case-control studies. Mol Biol Rep 39: 7143-7154, 2012.
39. von Euw EM, Barrio MM, Furman D, Levy EM, Bianchini M, Peguillet I, Lantz O, Vellice A, Kohan A, Chacon M, Yee C, Wainstok R and Mordoh J: A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of disease progression. J Transl Med 6: 6, 2008.
40. Kang JM, Kim N, Lee DH, Park JH, Lee MK, Kim JS, Jung HC and Song IS: The effects of genetic polymorphisms of IL-6, IL- 8, and IL-10 on Helicobacter pylori-induced gastroduodenal diseases in Korea. J Clin Gastroenterol 43: 420-428, 2009.
41. Barbisan G, Perez LO, Contreras A and Golijow CD: TNF-α and IL-10 promoter polymorphisms, HPV infection, and cervical cancer risk. Tumour Biol 33: 1549-1556, 2012.
42. Ioana Braicu E, Mustea A, Toliat MR, Pirvulescu C, Konsgen D, Sun P, Nurnberg P, Lichtenegger W and Sehouli J: Polymorphism of IL-1α, IL-1β and IL-10 in patients with advanced ovarian cancer: Results of a prospective study with 147 patients. Gynecol Oncol 104: 680-685, 2007.
43. Faupel-Badger JM, Kidd LC, Albanes D, Virtamo J, Woodson K and Tangrea JA: Association of IL-10 polymorphisms with prostate cancer risk and grade of disease. Cancer Causes Control 19: 119-124, 2008.
44. Lee JY, Kim HY, Kim KH, Kim SM, Jang MK, Park JY, Lee JH, Kim JH and Yoo JY: Association of polymorphism of IL-10 and TNF-α genes with gastric cancer in Korea. Cancer Lett 225: 207-214, 2005.